Healio Minute, Breast Cancer Edition: Top Headlines for the Week of December 12, 2022
Click Here to Manage Email Alerts
In this episode, FDA grants fast track designation to REM-001; practice-changing treatment advances continue; proton partial breast radiotherapy appears effective and more.
Read the full coverage here:
FDA grants fast track designation to REM-001 for cutaneous metastatic breast cancer
Practice-changing treatment advances continue in early-stage triple-negative breast cancer
Proton partial breast radiotherapy appears effective, safe for early breast cancer
New endocrine therapy options for patients with breast cancer on the horizon, expert says
Use of contraception decreases after breast cancer diagnosis
References:
Choi JI, et al. Clin Transl Radiat Oncol. 2022;doi:10.1016/j.ctro.2022.08.013
Healio Interviews
Lambertini M, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetowrkopen.2022.33137.
Traina TA, et al. Early-stage triple-negative breast cancer. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022.
Collapse
Click Here to Manage Email Alerts
